Search Results - "Pylypenko H"

POST-INDUSTRIAL TRANSFORMATIONS OF SOCIETY AND THEIR IMPACT ON THE EMPLOYMENT STRUCTURE.

Authors: Prushkivska, E. V. Pylypenko, Y. I. Tkachuk, A. M. et al.

Source: Scientific Bulletin of National Mining University; 2025, Issue 5, p177-187, 11p

A METHODOLOGICAL APPROACH TO ASSESSING THE PARAMETERS OF TECHNOLOGICAL CHANGE IMPACT ON THE ECONOMIC SUSTAINABILITY OF ENTERPRISES.

Authors: Prokhorova, V. Yemelyanov, O. Koleshchuk, O. et al.

Source: Scientific Bulletin of National Mining University; 2025, Issue 4, p227-236, 10p

TRANSITION TO A NEW PARADIGM OF HUMAN CAPITAL DEVELOPMENT IN THE DYNAMIC ENVIRONMENT OF THE KNOWLEDGE ECONOMY.

Authors: Pylypenko, Yu. Pylypenko, H. Prokhorova, V. V. et al.

Source: Scientific Bulletin of National Mining University; 2021, Issue 6, p170-176, 7p

COST EVALUATION MODELS OF R&D PRODUCTS OF INDUSTRIAL ENTERPRISES.

Authors: Pylypenko, H. M. Prokhorova, V. V. Mrykhina, O. B. et al.

Source: Scientific Bulletin of National Mining University; 2020, Issue 5, p163-170, 8p

PARADOXES OF ECONOMIC DEVELOPMENT: SCIENCE AND INNOVATION IN THE MODERN WORLD.

Authors: Pylypenko, H. Fedorova, N. Huzenko, I. et al.

Source: Scientific Bulletin of National Mining University; 2020, Issue 2, p153-159, 7p

PATHWAY OF THE INSTITUTIONAL DEVELOPMENT: PRACTICE OF LIBERAL TRANSFORMATION IN UKRAINE AND BELARUS.

Authors: Pylypenko, Yu. Pylypenko, H. Lytvynenko, N. et al.

Source: Scientific Bulletin of National Mining University; 2019, Issue 4, p120-127, 8p

INSTITUTIONAL COMPONENTS OF SOCIO-ECONOMIC DEVELOPMENT.

Authors: Pylypenko, Yu. Pylypenko, H. Lytvynenko, N. et al.

Source: Scientific Bulletin of National Mining University; 2019, Issue 3, p164-171, 8p

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Authors: Kiladjian JJ Klade C Georgiev P et al.

Corporate Authors: Kiladjian JJ Klade C Georgiev P et al.

Source: HemaSphere [Hemasphere] 2025 May 03; Vol. 9 (5), pp. e70137. Date of Electronic Publication: 2025 May 03 (Print Publication: 2025).

Publication Type: Letter

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Authors: Delimpasi S Mateos MV Auner HW et al.

Source: American journal of hematology [Am J Hematol] 2022 Mar 01; Vol. 97 (3), pp. E83-E86. Date of Electronic Publication: 2021 Dec 29.

Publication Type: Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Authors: Richard S Chari A Delimpasi S et al.

Source: American journal of hematology [Am J Hematol] 2021 Sep 01; Vol. 96 (9), pp. 1120-1130. Date of Electronic Publication: 2021 Jul 05.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Authors: Auner HW Gavriatopoulou M Delimpasi S et al.

Source: American journal of hematology [Am J Hematol] 2021 Jun 01; Vol. 96 (6), pp. 708-718. Date of Electronic Publication: 2021 May 03.

Publication Type: Comparative Study; Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Authors: Mateos MV Gavriatopoulou M Facon T et al.

Source: Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 13; Vol. 14 (1), pp. 59. Date of Electronic Publication: 2021 Apr 13.

Publication Type: Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Authors: Luke JJ Patel MR Blumenschein GR et al.

Source: Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2814-2824. Date of Electronic Publication: 2023 Oct 19.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Authors: Gisslinger H Klade C Georgiev P et al.

Corporate Authors: Gisslinger H Klade C Georgiev P et al.

Source: Leukemia [Leukemia] 2023 Oct; Vol. 37 (10), pp. 2129-2132. Date of Electronic Publication: 2023 Aug 26.

Publication Type: Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study^.

Authors: Robak T Huang H Jin J et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 172-179. Date of Electronic Publication: 2017 Jun 05.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Authors: Kiladjian JJ Klade C Georgiev P et al.

Corporate Authors: Kiladjian JJ Klade C Georgiev P et al.

Source: Leukemia [Leukemia] 2022 May; Vol. 36 (5), pp. 1408-1411. Date of Electronic Publication: 2022 Feb 24.

Publication Type: Research Support, Non-U.S. Gov't; Letter

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Authors: Grosicki S Simonova M Spicka I et al.

Source: Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1563-1573.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Authors: Gisslinger H Klade C Georgiev P et al.

Source: HemaSphere [Hemasphere] 2020 Oct 20; Vol. 4 (6), pp. e485. Date of Electronic Publication: 2020 Oct 20 (Print Publication: 2020).

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Authors: Kipps TJ Eradat H Grosicki S et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (10), pp. 2826-33. Date of Electronic Publication: 2015 May 12.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Authors: Gisslinger H Klade C Georgiev P et al.

Corporate Authors: Gisslinger H Klade C Georgiev P et al.

Source: The Lancet. Haematology [Lancet Haematol] 2020 Mar; Vol. 7 (3), pp. e196-e208. Date of Electronic Publication: 2020 Jan 31.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE